TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06383078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HR070803
Description: HR070803 60 mg/\^2 D1 over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR070803
Description: HR070803 60 mg/\^2 D1 over 90 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/\^2 D1 over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/\^2 D1 over 2 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: initial dose of S-1 is determined according to the body surface area，orally, D1-7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic acid
Description: Folinic acid 400 mg/\^2 D1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 5-FU 2400 mg/\^2 D1 IV continuous infusion over 46 hours
Study: NCT04524910

Intervention type: DRUG
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Description: As prescribed by the treating physician
Study: NCT06024590

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irrisept
Description: Standard of care wound treatment with 150 mL of IrriseptTM irrigation of the wound at each follow up visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Standard of care wound treatment with 150 mL ration of Normal saline irrigation of the wound at each follow up visit
Study: NCT04911881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI321
Description: Several dose levels will be evaluated for IBI321 administered as a single agent. IBI321 will be given via IV infusion on Day 1 of each cycle until disease progression or loss of clinical benefit.
Study: NCT06486376

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water, Sanitation and Hygiene Education Against Diarrhoea, Undernutrition and Pneumonia
Description: Intervention components include teacher training, stepdown training of teachers to children and distribution of IEC materials.
Study: NCT04022850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A non-reflective decision assistance strategy
Description: A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A non-reflective decision assistance strategy
Description: A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).
Study: NCT06289153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: All patients will undergo ACL reconstruction (ACLR) with or without an internal brace.
Study: NCT06303037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate and low-dose Esketamine
Description: Esketamine was injected intravenously 0.25mg/kg and the initial dose of Remimazolam was 0.3mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate and Medium dose Esketamine
Description: Esketamine was injected intravenously 0.5mg/kg and the initial dose of Remimazolam was 0.2mg/kg
Study: NCT05944601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual and computer-based cognitive remediation training
Description: Amyloid-positive MCI patients, and individuals carrying the ApoE- ε4 allele will undergo a combined intervention of computer-based sessions of a spatial memory task by the Erica software (Giunti, Florence, Italy) and VR navigation sessions by the NeuroVirtual 3D software (Serino et al., 2010), in order to improve spatial memory for landmarks location and mental frame syncing for supporting spatial scenarios, respectively. The intervention will last one month for a total of 12 sessions (3 days a week, 50 minutes per session).
Study: NCT06506162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: The study will compare sweet vs. cool flavors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: The study will compare sweet vs. cool flavors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: The study will compare sweet vs. cool flavors
Study: NCT05190978

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction without ADM
Description: Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
Study: NCT05115370

Intervention type: OTHER
Intervention: Semi-structured qualitative interview
Description: A single semi-structured qualitative interview conducted face-to-face or by telephone or video-conference call.
Study: NCT05071612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD109
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD504
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD504
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine Hydrochloride
Description: Oral administration at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration at bedtime
Study: NCT05976477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: 1. four short videos (about one-minute/one-minute and half duration) concerning the topic of reducing dietary salt intake to control the blood pressure in elderly hypertensive patients: the mini-videos will be designed with a common thread starting from providing general information regarding diet to enhance awareness of the amount of salt that is usually introduced with the diet, up to give suggestions on which products to choose/avoid during grocery shopping and how to behave during the preparation and consumption of food at home to reduce salt intake;~2. Four images informing participants about the risk of excessive salt intake and health benefits of a low-sodium diet and tips on how to reduce daily salt intake;~3. Four recipes for tasty easy-to-prepare meals, avoiding added salt.
Study: NCT05071612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration at bedtime
Study: NCT04776161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-Reward Intervention
Description: Patients in the first intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Patients will also receive text messages reminding them of the habit they decided to link to their medication-taking.~Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-Reward Intervention with possible intensification
Description: Patients in the second intervention arm will participate in a goal-setting exercise during which they will identify which habit they want to link their medication-taking to. Finally, patients will also select a charity to which a donation will be made every time the bottle is opened. The research team will donate $0.50 every day that the patient takes their medication as prescribed. A research assistant will place a sticker with the charity logo under the pill bottle cap so that the patient is reminded of the donation every time they take the medication. Additionally, the patient will receive texts every 4 days summarizing how much money was donated on their behalf.~After 6 weeks, patients who demonstrate an adherence under 80% to study medications (as measured by the electronic pill bottle) will begin receiving text messages reminding them of their selected cue.
Study: NCT06119516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal pressure-guided strategy,
Description: A catheter-balloon system will be positioned and calibrated in all included patients. The second generation esogastric multifunction Nutrivent catheter (SIDAM, Mirandola, Italy) will be used. It allows both enteral nutrition of the patients and monitoring of esophageal and gastric pressures during several days. A connection line will be inserted between the catheter (either esophageal or gastric balloon port) and the auxiliary pressure port of the mechanical ventilator (General Electric, R860, available in each center). Numeric recording of the respiratory signals will be achieved via the OhmedaCom Research Tool software, helping for centralization of the analyses, therefore ensuring reproducibility of the results.
Study: NCT04598711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC
Description: See descriptions under arm/group descriptions. RLIC is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Conditioning
Description: See descriptions under arm/group descriptions. Sham conditioning is delivered for 14 visits. Visits 1-3 occur on consecutive work days and visits 4-14 occur on alternating week days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Power training
Description: All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Muscle Power training
Description: All participants undergo power training of the quadriceps muscles using unilateral and bilateral leg presses (Total Gym GTS, San Diego, CA), 3 times/week for 4 consecutive weeks (12 sessions). Power training will follow standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Power training is provided at visits 3-14.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-14.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treadmill Training
Description: All participants will undergo short burst interval treadmill training using self-selected and fast walking speeds.
Study: NCT06527859

Intervention type: DRUG
Intervention: Levothyroxin
Description: The disease group were divided into two groups ,25ugLT4 (HA group, n=17) and 50ugLT4 (HB group, n=17) respectively.
Study: NCT04022850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A non-reflective decision assistance strategy
Description: A strategy based on providing evidence-based information communication technology tools to help and guide decision-making: pop-up reminders and alerts with associated messages incorporated into the REGICOR CVR calculator in OSABIDE (Osakidetza's EHR system) and within the prescription pathway in PRESBIDE (the electronic drug prescribing component).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A both reflective and non-reflective decision information strategy
Description: This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients.
Study: NCT06506162

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavor
Description: The study will compare sweet vs. cool flavors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine concentration
Description: The study will compare low vs. high strength Oral Nicotine Products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine concentration
Description: The study will compare low vs. high strength Oral Nicotine Products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine concentration
Description: The study will compare low vs. high strength Oral Nicotine Products

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine concentration
Description: The study will compare low vs. high strength Oral Nicotine Products
Study: NCT05811806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment using the MyHand System
Description: Participants will undergo three weeks of 1-hour hand therapy with the MyHand System. The MyHand System provides a highly unique and targeted approach to hand function rehabilitation with the help of the aforementioned protocols delivered with gamified training techniques. The gamified format of the protocols allows for better patient engagement, thus allowing for more effective and efficient therapy.
Study: NCT06270212

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STAIRWAY
Description: Evaluation of STAIRWAY (new airway device) during sedation.

Intervention type: DEVICE
Group type: OTHER
Intervention: NO DEVICE
Description: Evaluation of NO DEVICE during sedation
Study: NCT04864405

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Morning administration of endocrine therapy
Description: Endocrine therapy administered within one hour of patient wake up time

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evening administration of endocrine therapy
Description: Endocrine therapy administered within one hour of the patient bed time
Study: NCT04601610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046 （PD-L1/CTLA4 BsAb）
Description: KN046 5mg/kg Q3W
Study: NCT06300177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-1553 Tablet
Description: D-1553 is a KRAS inhibitor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
Study: NCT02337894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential amino acids plus arginine
Description: Flavored drink containing essential amino acids plus arginine.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flavored drink without essential amino acids plus arginine.
Study: NCT06191692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine
Description: This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampicin
Description: This randomized control trial will compare the treatment adherence and safety of the 1HP (Arm B) regimen and standard 3HR (Arm A) regimens for TB infection treatment
Study: NCT05069727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular Protocol with advanced carbohydrate counting
Description: * Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD~* Finetune ICR~* Target 100 or 110 mg/dl~* AIT: 2-3 hour~* Insulin Bolus for meal (advanced carb counting)~* The parameters will be set using clinical assessment and fine-tuned if needed on F-up visits.~* Follow up visits will be scheduled Day 7, 14,28, 56 and 84 after enabling SmartGuard (AHCL use).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simplified Protocol with fixed carbohydrate content
Description: * Review 3 Days CGM data in Manual Mode~* Carb Ratio by formula 360 / TDD ICR 8-10 (TDD 40-60) ICR 5-7 (TDD \>60)~* Target 100 mg/dl~* AIT: 2 hours~* Insulin Bolus for meal (Thee sets of meal set of meals announcement carbs will be provided) Regular meal: Total Carbs per Day x 0.6 / 3 Large meal: Total Carbs per Day x 0.6 / 3 x 1.5 Small (Snack) meal: Total Carbs per Day x 0.6 / 3 x 1.5~* Total carbs per day will be calculated as average on 7-days Food Logbook diary, provided by participant, one week before AHCL initiation.~* The parameters will be fixed and fine-tuned only in case of hypoglycemia on F-up visits.
Study: NCT05299177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InControl
Description: Automated insulin delivery system comprising continuous glucose sensor (Dexcom G6), controller (InControl embedded in smartphone app) and insulin pump (YpsoMed Ypsopump)
Study: NCT05077839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Trifluridine/tipiracil was approved in the third-line treatment of advanced colorectal cancer. Its efficacy in the first-line treatment was unknown.
Study: NCT04022850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A both reflective and non-reflective decision information strategy
Description: This strategy consists of a corporate campaign entitled Stopping Low-Value Prescribing run by the organization (Osakidetza- Basque Health Service) that provides FPs with the evidence-based Clinical Practice Guidelines for the primary prevention of CVD in low-risk patients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A reflective decision structure strategy
Description: The strategy involves the sending of regular audit/feedback reports with practice- and organizational-level performance indicators regarding PIP of statins and healthy lifestyle promotion to prompt reflection about their own care practice, provided along with intention formation and goal-setting-focused messages.
Study: NCT05706532

Intervention type: DIAGNOSTIC_TEST
Intervention: active standing
Description: Data are acquired with patients resting in supine position for 10 minutes and for 10 minutes during active standing
Study: NCT04545918

Intervention type: DEVICE
Intervention: Follicle Clarity
Description: Mask Region-based Convolutional Neural Network in Ultrasound Follicle Identification
Study: NCT04601610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046 （PD-L1/CTLA4 BsAb）
Description: KN046 5mg/kg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningetinib Tosylate（multi-target TKI）
Description: ningtinib QD, dose will be decided by investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningetinib Tosylate（multi-target TKI）
Description: ningtinib QD, dose will be decided by investigator
Study: NCT05254353

Intervention type: PROCEDURE
Intervention: Analyses of proximal and distal samples
Description: Evaluate the difference between proximal and distal CSF samples
Study: NCT06148168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus normal saline
Description: Unlike specific peripheral nerve blocks, TAP block is a non-dermatomal field block. Even with the same US-guided technique, the extent of spread of local anesthetics can be variable due to individual anatomical variations (18). In order to perform the blocks, abdominal skin will be prepared and covered with sterile drapes. The needle can be introduced by multiple punctures along the oblique subcostal line from the xiphoid process towards the anterior part of the iliac crest .Thus, LA will be injected in the TAP along this line provides both upper and lower abdominal wall analgesia. The OSCTAP block more consistently covers L1 dermatome. After negative aspiration, a test injection with 1 ml of 0.9% normal saline will be performed to confirm the needle location. If the intended sensation will not decreased in surgical dermatomes after 30 min, the patient will be regarded to have a failed block and will be excluded from the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus normal saline containing MgSO4
Description: Bupivacaine plus normal saline containing MgSO4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine plus normal saline containing MgSO4
Description: Bupivacaine plus normal saline containing MgSO4